India Firm Zydus Cadila Takes Teva To U.S. Court Over Risperidone APIs
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian drug maker’s case argues Teva is interfering with its present and future business.
You may also be interested in...
U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon
MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.